X4 Pharmaceuticals Appoints Experienced Biotech CFO Kelly Gold to Board
XFOR has more than doubled off its 52-week low of $1.35.
Summary
X4 Pharmaceuticals appointed Kelly Gold, an experienced biotech CFO, to its Board of Directors and Audit Committee, enhancing the company's financial and strategic oversight.
Key Events · Executive and Board Changes · XFOR
-
New Director Appointment
Kelly Gold was appointed as a Class II director, effective July 1, 2026, increasing the board size from five to six members.
-
Strengthened Financial Expertise
Ms. Gold, currently CFO of CAMP4 Therapeutics, brings significant financial leadership, capital markets, and strategic planning experience from her roles at CAMP4, Biogen, and Deutsche Bank.
-
Audit Committee Role
Ms. Gold will also serve on the Audit Committee, enhancing financial oversight for the company.
Analysis · XFOR · Life Sciences
X4 Pharmaceuticals has strengthened its board by appointing Kelly Gold, a seasoned Chief Financial Officer from another public biopharmaceutical company, to its Board of Directors and Audit Committee. Her extensive background in financial leadership, capital markets, and strategic planning within the biotech sector is a significant addition, particularly as the company continues to advance its lead product, XOLREMDI, and manage its financial trajectory.
At the time of this filing, XFOR was trading at $4.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $385.3M. The 52-week trading range was $1.35 to $4.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.